Dr Farah Louise Lim

Dr Farah Louise Lim

MBBS (HONS) BSC MRCP (MED ONC)

Consultant Medical Oncologist/Immune-oncologist

I qualified from Imperial School of Medicine in 2004 with distinction in clinical practise and 1st class Honors in molecular biology and trained in medical oncology at St Bartholomew’s hospital. I completed post graduate training in medical oncology in 2012, and further specialist training in immune-oncology in solid tumours (breast/GU/Lung) which finished in 2017. I was appointed a consultant at St Bartholomew’s hospital leading the lung immunotherapy/clinical trials unit in 2017.

I have extensive experience in immune-oncology and to date have treated a wide variety of solid tumours with immunotherapy. I frequently lecture about immunotherapy and have formed a formal educational immunotherapy teaching group in the Barts clinical trials unit.

I specialise in lung cancer particularly in the area of immunotherapy/targeted therapy.

I currently lead the immunotherapy trials unit within lung cancer at Barts Heath. This team consists of specialist nurses and clinical trial practitioners as well as clinical fellows training in immunotherapy.

Our current trials portfolio consists of phase I-III studies, looking at combinations of immunotherapy agents with chemotherapy in combination. We also have an extensive portfolio of trials looking at molecular gene mapping targeting specific genes in lung cancer.

I am dedicated to providing the highest standard of care in oncology to both patients and their families.

Research and Publications

I am the lead for lung cancer research at St Bartholomew’s hospital, and lead a number of global lung immunotherapy trials.

My work focuses on a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They exploit functional imaging and tissue collection.

Alongside these trials, my research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy.

I have written numerous peer review papers in this area.

LOC 95 Harley Street
LOC at Chelsea